COLLABORATIVE ARRANGEMENTS (Details 3) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Nov. 30, 2012 Research Collaboration and License Agreement Merck Novel small molecule therapeutics Item	Sep. 30, 2013 Research Collaboration and License Agreement Merck Novel small molecule therapeutics	Sep. 30, 2013 Research Collaboration and License Agreement Merck Novel small molecule therapeutics	Oct. 31, 2012 Research Collaboration and License Agreement Merck Novel small molecule therapeutics Maximum
Information related to collaborative arrangements
Upfront payment					$ 5,000,000
Potential future contingent payments receivable								148,000,000
Initial research term					12 months
Number of units of accounting based on the relative selling price method					3
Upfront payment received allocated to license					4,400,000
Upfront payment received allocated to research services					400,000
Upfront payment received allocated to committee participation					200,000
Increase in revenue due to revised estimated performance period						37,000
Revenues	$ 439,000	$ 1,430,000	$ 3,110,000	$ 129,960,000		$ 41,000	$ 51,000